Modern (NASDAQ: MRNA) had quite a year.
The development of a vaccine that can help bring about the end of a pandemic could apparently increase a company’s share price. How much happiness did Moderna then produce for its shareholders in 2020? Let’s see.
Image Source: Getty Images.
Moderna delivered a much-needed ray of hope to the world in November, when a phase 3 clinical trial showed that the coronavirus vaccine candidate mRNA-1273 was 94.1% effective against COVID-19 – and as much as 100% effective to prevent severe cases of the disease.
In addition, it was found that Moderna’s vaccine was generally safe and well tolerated, without any serious safety issues among the more than 30,000 participants in the study.
The world rejoices. And investors have responded by offering Moderna shares, which had already risen sharply at the time, based on earlier progress in developing the coronavirus vaccine.
Overall: from 11:45 a.m. EST on December 31st, Moderna’s share price will increase by 446% in 2020. So, for every $ 1,000 you invested in Moderna in January, you would have almost $ 5,500 today.
Even more profits could ahead of Moderna investors in 2021. The biotechnology company plans to use the profits it makes from the sales of mRNA-1273 to finance the development of new vaccines for other diseases. Should one or more of them be safe and effective, Moderna – and its shareholders – could have even more good years.